How to Use Risk-Based Monitoring and Clinical CAPA to Ensure Compliance

This white paper will discuss the importance of risk-based monitoring and CAPA in clinical research within the context of the following initiatives by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA): 2013 Guidance Clinical Trial Transformation Initiative (CTTI) EMA's Reflection Paper on Risk-Based Quality Management in Clinical Trials Request Free!